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Summary: To describe the frequency, risk factors, and clinical signs and symptoms associated with hepatotoxicity (HT) in
patients on nevirapine- or efavirenz-based antiretroviral therapy (ART), we conducted a retrospective cohort analysis of patients
attending the ART clinic in Kibera, Kenya, from April 2003 to December 2006 and in Mavalane, Mozambique, from December 2002 to
March 2007. Data were collected on 5832 HIV-positive individuals who had initiated nevirapine- or efavirenz-based ART. Median
baseline CD4þ count was 125 cells/mL (interquartile range [IQR] 55–196). Over a median follow-up time of 426 (IQR 147–693) days,
124 (2.4%) patients developed HT. Forty-one (54.7%) of 75 patients with grade 3 HT compared with 21 (80.8%) of 26 with grade
4 had associated clinical signs or symptoms (P ¼ 0.018). Four (5.7%) of 124 patients with HT died in the ﬁrst six months
compared with 271 (5.3%) of 5159 patients who did not develop HT (P ¼ 0.315). The proportion of patients developing HT was low
and HT was not associated with increased mortality. Clinical signs and symptoms identiﬁed 50% of grade 3 HT and most cases
of grade 4 HT. This suggests that in settings where alanine aminotransferase measurement is not feasible, nevirapine- and
efavirenz-based ART may be given safely without laboratory monitoring.
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INTRODUCTION
The majority of antiretroviral therapy (ART) programmes in
sub-Saharan African countries are scaling up ﬁrst-line ART
using ﬁxed dose antiretroviral regimens containing stavudine
(d4T), lamivudine (3TC) and nevirapine (NVP).
1,2 In
HIV-positive patients with tuberculosis (TB), efavirenz (EFV)
replaces NVP. One of the primary concerns with these regimens
is hepatotoxicity (HT) associated with NVP.
3–10 In a
meta-analysis of controlled clinical trials, the risk of HT associ-
ated with NVP was 10%.
7 In a trial conducted in South Africa,
this was as high as 17%.
6 In resource-rich countries, screening
for HT during ART has been primarily based on serum
alanine aminotransferase (ALT) levels, a liver enzyme that
serves as a ‘proxy’ for liver inﬂammation and damage. HT is
graded into four categories (grades 1–4) and severe HT
implies grade 3 and grade 4 toxicity. Grade 3 toxicity is
deﬁned as an ALT .5 times the upper limit of the normal
range (ULN) and grade 4 HT as an ALT .10 times the
ULN.
11 Clinical guidelines recommend discontinuation of
NVP or EFV at grade 3 or 4 HT.
12 The correlation of
NVP-related HT with clinical symptoms remains poorly docu-
mented and ranges from 2% to 17% in the literature.
13
ALT testing requires laboratory technology that is sophisti-
cated and expensive and therefore not routinely available at
the health centre level in most resource-poor settings. In order
that ALT testing does not act as a barrier to scaling up ART in
such settings, World Health Organization (WHO) guidelines
do not insist on ALT monitoring as a prerequisite to offering
ART at the primary care level.
1 This, however, is in contrast to
manufacturer guidelines that recommend vigilant ALT monitor-
ing for NVP users for the ﬁrst 18 weeks, and regular monitoring
thereafter while on treatment.
3 Clinical trials support routine
monitoring in the ﬁrst 12 weeks
6,14,15 but it is unknown if
routine ALT testing prevents morbidity or mortality in routine
programme settings. Risk factors for HT in resource-constrained
settings in sub-Saharan Africa are not well described.
This cohort study of adults commenced on ﬁrst-line NVP- or
EFV-containing ART regimens under programmatic conditions
in Mozambique and Kenya describes the frequency of HT,
examines possible risk factors associated with HT, and
describes the relationship between elevated ALT levels and
clinical symptoms and signs.
METHODS
Study setting and population
This study included patients from Mavalane, Mozambique, and
Kibera, Kenya, where ART has been provided by Me ´decins
Correspondence to: Kathryn Chu
Email: kathryn.chu@joburg.msf.org
DOI: 10.1258/ijsa.2009.009328. International Journal of STD & AIDS 2012; 23: 403–407Sans Frontie `res (MSF) since 2002 and 2003, respectively, in col-
laboration with the Ministries of Health. All patients are started
on either NVP- or EFV-based triple therapy according to WHO
guidelines for the provision of ART in resource-limited settings.
The majority of patients were given the nucleoside backbone of
d4T plus 3TC. Patients who had at least one follow-up visit and
initiated ART in Kibera, Kenya, from April 2003 to December
2006 and in Mavalane, Mozambique, from December 2002 to
March 2007 were included. Women who had previously
received single or dual NVP-based therapy via the prevention
of mother-to-child transmission (PMTCT) programme were
also included. Treatment-experienced patients and children
were excluded.
ALT measurements and HT
ALT testing was systematically offered to all patients at baseline,
two weeks, four weeks, then every six months, and when
clinically indicated. Laboratory testing was performed by the
respective hospital laboratories with quality control ensured
by MSF. ALT assays were conducted using a spectrophotometer
following standard operating procedures. Clinical symptoms
and signs consistent with hepatitis were nausea, vomiting,
abdominal pain and/or jaundice. Serum ALT (units/litre) was
graded using criteria established by the AIDS Clinical Trial
Group
11 as follows: grade 0 ¼ ,1.25   ULN; grade 1 ¼ 1.25–
2.5   ULN; grade 2 ¼ 2.6–5.0   ULN; grade 3 ¼ 5.1–10  
ULN; grade 4 ¼ .10   ULN. HT was deﬁned as grade 2 ALT
with associated clinical symptoms, or grade 3 or 4 ALT.
Severe HT was deﬁned as grade 3 or 4 ALT. HT was
managed according to national and WHO guidelines, which
recommend that NVP or EFV be substituted or stopped when
grade 3 or 4 ALT or grade 2 ALT with clinical symptoms ensue.
Statistical analysis
Baseline characteristics and ART outcomes for all patients
initiated on NVP- or EFV-based ART were exported from an
electronic database maintained prospectively for routine moni-
toring and evaluation. Patients who stopped or substituted
NVP or EFV because of potential HT were identiﬁed using
this database and HT conﬁrmed through chart review.
Mortality was evaluated up to six months after initiation of
ART since those occurring later were unlikely to be attributed
to HT. Data were analysed using Stata (Version 10, College
Station, TX, USA). Time from treatment initiation to HT event
was estimated using the Kaplan–Meier method. Cox pro-
portional hazards regression analysis was used to determine
risk associated with HT. Logistical regression was used to deter-
mine risk factors for clinical signs and symptoms. Variables
considered in the analyses included age, gender, baseline
CD4 cell count, type of non-nucleoside reverse transcriptase
inhibitor (NNRTI) (NVP or EFV), and programme site. The
chi-squared test was used for determining the relationships
between HT and mortality and to compare the association of
grade of HT with clinical grades 3 and 4 HT. All available vari-
ables were included a priori in multivariate models. All tests
and conﬁdence intervals were considered to be signiﬁcant at
a P   0.05 (two-sided).
Ethics
The HIV/AIDS programmes in the two countries have been for-
mally approved by the respective Ministries of Health. The pro-
cedures for selection and inclusion of patients within the ART
programme follow WHO and national guidelines. General
measures are provided to ensure patient conﬁdentiality,
consent for HIV testing, and counselling and support for
those who receive a positive HIV test result. ART and all labora-
tory testing services (including ALT) are offered free of charge
within the two projects. Ethical approval was given by an inde-
pendent Ethics Review Board that screens research proposals
by MSF.
RESULTS
Characteristics of the study population
During the study period, 5283 HIV-infected, ART-naı ¨ve indi-
viduals were initiated on NVP- or EFV-based ART. Of these,
4773 (90.4%) were started on NVP. In total, 35% (1858) were
men; median baseline CD4 count was 125 cell/mL (IQR 55–
196) and median follow-up time on ART was 426 days (IQR,
147–693). At the end of the follow-up period, 4331 (82%) of
the cohort were still alive and on ART, 154 (3%) were trans-
ferred out, 388 (7%) died and 502 (10%) were lost to follow
up (LTFU). The median time to LTFU was 180 days (IQR 59–
405 days). Baseline characteristics and ART outcomes are
shown in Table 1.
Table 1 Baseline characteristics and outcomes of patients on nevirapine- and efavirenz-based antiretroviral therapy
Kenya (n 5 2032) Mozambique (n 5 3251) Combined (n 5 5283)
NVP-based ART 1883 (92.7) 2890 (88.9) 4773 (90.4)
EFV-based ART 149 (7.3) 361 (11.1) 510 (9.7)
Males 695 (34.2) 1163 (35.8) 1858 (35.2)
Age on starting ART (years) 33 (28–39) 34 (28–42) 34 (28–41)
Baseline CD4þ count, (cell/mL) 140 (70–205) 115 (47–189) 125 (55–196)
Baseline WHO stage 3 or 4 1408 (69.3) 2272 (69.9) 3680 (69.7)
Follow-up time on ART (days) 349 (119–622) 477 (170–713) 426 (147–693)
Remaining in care 1658 (81.6) 2673 (82.2) 4331 (82.0)
LTFU 114 (5.6) 388 (11.9) 502 (9.5)
Transferred out 135 (6.6) 19 (0.6) 154 (2.9)
Died 125 (6.2) 268 (8.4) 388 (7.3)
Hepatotoxicity 43 (2.1) 81 (2.5) 124 (2.4)
Continuous variables are given as median (interquartile range). Ordinal and discrete variables are given as n (%). WHO ¼ World Health Organization; NVP ¼ nevirapine;
EFV ¼ efavirenz; ART ¼ antiretroviral therapy; LTFU ¼ lost to follow-up; BMI ¼ body mass index; HT ¼ hepatotoxicity
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Overall, one hundred and twenty-four (2.4%) patients developed
HT while on NVP- or EFV-based ART. This rate was similar if
only women starting ART at CD4.250 cells/mL were con-
sidered: 12 HT events among 409 women (2.9%). Median time
to HT was 43 days (IQR, 28–81) in the Kenya cohort and 46
days (IQR, 29–110) in the Mozambique cohort. Eleven (0.2%)
individuals had grade 2 HT, 83 (1.5%) had grade 3 HT and
30 (0.5%) had grade 4 HT. Of 20 men starting ART with a
CD4 . 400/mL, only one (5%) developed HT. Times to HT are
shown in Figures 1 and 2. Ninety-four (76%) episodes of HT
occurred in the ﬁrst three months on ART. Of patients with
HT, 111 (89.5%) had data on associated clinical symptoms avail-
able and 72 of these (64.8%) were clinically symptomatic
(Table 2). On multivariate analysis, age, gender, type of
NNRTI, baseline CD4 count and programme site were not
associated with HT or clinical symptoms (Tables 2 and 3). All
(100%) patients with grade 2 HT had clinical symptoms.
Forty-one (54.7%) of patients with grade 3 (n ¼ 75) and 21
(80.8%) of patients with grade 4 HT (n ¼ 26) had associated clini-
cal signs or symptoms (P ¼ 0.018). On multivariate analysis,
grade 4 HT (compared with grade 3 HT) was found to be inde-
pendently associated with clinical symptoms (odds ratio [OR] ¼
3.72, 95% CI 1.16–10.39, P ¼ 0.023). Four (5.7%) of 124 patients
with HT died in the ﬁrst six months compared with 271 (5.3%)
of 5159 patients who did not develop HT (P ¼ 0.315). After
adjusting for gender, age, CD4 count, ART drug and clinic
location, HT was not found to be a risk factor for mortality
(hazard ratio [HR] ¼ 0.53, 95% CI 0.20–1.42, P ¼ 0.205) (Table 4).
DISCUSSION
In this study the proportion of patients developing HT was low
and not associated with increased mortality. Median time to HT
was approximately six weeks. Clinical signs and symptoms
alone identiﬁed half of grade 3 toxicity and most cases of
grade 4 HT. This suggests that in settings where ALT measure-
ments are not possible, NVP- and EFV-based ART might be
given safely without laboratory monitoring.
In our setting, 2.4% of patients discontinued ART due to HT.
Reports in the literature of NVP-associated HT have ranged
from 2% to 18% with variable deﬁnitions of HT including
asymptomatic ALT elevation, clinical symptoms consistent
with hepatitis or a combination of both.
6,16 Few studies have
reported on the frequency of discontinuation of ART due to
HT in routine programmatic settings. In Thailand, 2% of
patients on NVP-based ART and 0.5% of patients on
EFV-based ART discontinued therapy due to HT.
17 In an
MSF multi-centre observational cohort, 11 (1.6%) of 655 discon-
tinued NVP-based ART due to HT.
18 While it has been rec-
ommended to stop NVP when asymptomatic grade 3 or 4
ALT elevation occurs,
4,12 morbidity and mortality associated
with isolated liver enzyme elevations are not well established.
NVP manufacturer inserts recommend ‘routine ALT testing
until 18 weeks’
4 but resource-constrained settings are chal-
lenged to do so given the limited availability of laboratory
monitoring.
Deﬁning risk factors for HT allows for selective ALT monitor-
ing for higher risk patients where routine ALT monitoring is
unavailable or prohibitively expensive. Conﬂicting data on
the association of baseline CD4 count and HT have been
reported. In some studies, higher baseline CD4 counts
(.400 cells/mL for men and .250 cells/mL for women) have
been associated with a greater risk for NVP-based HT;
19 other
studies did not demonstrate such an association.
20,21
Considering our median CD4 count (125 cells/mL) was low
we could not assess the risk of HT accurately for those with
high baseline CD4 counts. One study found a marginal associ-
ation between low baseline CD4 count (,100 cells/mL) and risk
of HT among patients on an EFV-based regimen
22 but we did
not ﬁnd such an association.
The correlation of clinical symptoms with ALT elevation has
not been well documented. In our study, the majority of
patients with severe HT had clinical signs or symptoms. This
suggests that grade 3 or 4 ALT alone without clinical symptoms
may not necessarily require immediate drug substitution. In a
meta-analysis of Boehringer Ingelheim-sponsored clinical
trials, 125 subjects continued NVP despite developing severe
(grades 3 and 4) HT and patients remained clinically asympto-
matic and resolved their ALT abnormalities without morbid-
ity.
7 In our study, HT was not associated with increased
Figure 1 Time to hepatotoxicity on nevirapine- or efavirenz-
based antiretroviral therapy
Figure 2 Time to early hepatotoxicity on nevirapine- or efavirenz-
based antiretroviral therapy
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HT in the most severe cases, and if drug-associated HT is
not associated with increased mortality, then routine ALT
monitoring may not be necessary. In Uganda, where ALT moni-
toring was unavailable, HT was reported in 0.5% of patients
and the cause of death in only one of 992 patients on
NVP-based ART.
2
This study has a number of limitations. The main limitation
was potential underreporting of HT. While both programmes
in Kenya and Mozambique had standard ALT monitoring, it
is unknown how well these were enforced. From a study in
South Africa, we demonstrated that few patients were moni-
tored according to protocol in the resource-constrained
setting.
23 HT detection will be greater the more frequently
ALT is monitored: in South Africa, patients who had ALT
measured at baseline, four weeks, eight weeks and 12 weeks
were more likely to develop HT during the ﬁrst three months
compared with those who had ALT measured less frequently.
23
We also do not know if patients who died or were lost to follow
up had HT and if so, whether this would have changed the
ﬁndings. Given that, on average, losses occurred among
patients who had been on treatment for six months, we con-
sider it unlikely that these would have been due to severe
hepatotoxic events. Another limitation is lack of data on associ-
ated risk factors for HT: alcohol use, concurrent TB treatment
and hepatitis co-infection were not measured in these routine
programmes
5,7 However, even though hepatitis co-infection
rates are likely around 10%,
24–26 HT remained low in this
study suggesting co-infection may not be a contraindication
to starting NVP- or EFV-based ART. One study reported low
body mass index as a risk factor for HT;
6 this could not be
assessed in our study as height was not routinely recorded.
Most patients were on ART that also included stavudine
(d4T), which may have been a contributor to late HT. This
effect was not measured in our study.
Nonetheless, we believe our ﬁndings have important public
health implications regarding HT and the use of ART. First,
HT associated with NVP- or EFV-based ART is rare in these
programmatic settings; second, clinical symptoms are usually
associated with severe HT; ﬁnally, HT was not associated
with increased mortality. ALT monitoring is a barrier to
scale-up of ART in resource-limited settings in sub-Saharan
Africa; these data suggest that clinical rather than ALT monitor-
ing might be sufﬁcient. Prospective studies are warranted to
conﬁrm our ﬁndings, particularly for patients initiating
NVP-based ART at higher CD4 counts.
Table 2 Adjusted associations between patient characteristics and hepatotoxicity
Univariate analysis Multivariate analysis 
HR 95% CI P HR 95% CI P
Male 1.06 (0.88–1.27) 0.536 1.09 (0.98–1.32) 0.388
Age on starting ART (years) 0.99 (90.97–1.01) 0.392 0.99 (0.97–1.01) 0.285
NVP-based ART (ref EFV) 1.10 (0.51–2.41) 0.798 1.12 (0.52–2.41) 0.775
Baseline CD4 count ,150 cells/mL 1.25 (0.88–1.79) 0.216 1.25 (0.87–1.79) 0.228
Kibera, Kenya (ref Malavane, Mozambique) 1.05 (0.73–1.52) 0.790 1.03 (0.71–1.50) 0.881
HR ¼ hazards ratio; NVP ¼ nevirapine; EFV ¼ efavirenz; HT ¼ hepatotoxicity; CI ¼ conﬁdence interval; ART ¼ antiretroviral therapy
 Adjusted for all variables
Table 3 Adjusted associations between patient characteristics and clinical symptoms and signs of hepatotoxicity
Unadjusted odds ratio Adjusted odds ratio 
OR 95% CI P OR 95% CI P
Male 0.90 (0.60–1.34) 0.611 0.96 (0.62–1.50) 0.870
Age on starting ART (years) 1.01 (0.96–1.06) 0.694 1.01 (0.96–1.07) 0.679
NVP-based ART (ref EFV) 0.72 (0.13–3.92) 0.708 1.18 (0.16–9.0) 0.872
Baseline CD4 count ,150 cells/mL 0.91 (0.41–1.98) 0.805 0.86 (0.16–9.0) 0.730
Kibera, Kenya (ref Malavane, Mozambique) 0.95 (0.41–2.20) 0.899 1.41 (0.54–3.68) 0.860
HT grade 4 versus grade 3 3.48 (1.19–10.22) 0.023 3.72 (1.16–10.39) 0.023
OR¼odds ratio; NVP¼nevirapine; EFV¼efavirenz; HT¼hepatotoxicity; ART ¼ antiretroviral therapy; CI ¼ conﬁdence interval
 Adjusted for all variables
Table 4 Adjusted associations between patient characteristics and mortality
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Male 1.29 (1.15–1.45) ,0.001 1.22 (1.08–1.38) ,0.001
Age on starting ART (years) 1.02 (1.01–1.03) ,0.001 1.01 (1.00–1.02) 0.066
NVP-based ART (ref EFV) 0.65 (0.46–0.93) 0.016 0.75 (0.53–1.06) 0.108
Baseline CD4 count ,150 cells/mL 2.08 (1.63–2.66) ,0.001 2.01 (1.57–2.56) ,0.001
Kibera, Kenya (ref Malavane, Mozambique) 1.22 (0.95–1.58) 0.112 1.16 (0.90–1.49) 0.260
HT 0.56 (0.21–1.51) 0.254 0.53 (0.20–1.42) 0.205
HR ¼ hazards ratio; NVP ¼ nevirapine; EFV ¼ efavirenz; HT¼hepatotoxicity; CI ¼ conﬁdence interval; ART ¼ antiretroviral therapy
 Six-month mortality
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